real peptides FAQ

Discard it. Reconstituted peptides in bacteriostatic water degrade at approximately 15–20% per week beyond the 28-day window, meaning a 35-day-old solution has lost 25–35% of its original potency. This degradation isn't visible. The solution remains clear and particle-free even as the peptide structure denatures. Using degraded peptides doesn't pose a safety risk, but it guarantees inconsistent results. If budget is a constraint, order smaller vial sizes that you'll use within 28 days rather than extending storage on larger batches.

Refuse the shipment and request replacement with temperature verification. Peptides exposed to ambient temperature (>25°C) for more than 6 hours undergo irreversible tertiary structure disruption. The amino acid sequence remains intact but the bioactive conformation is destroyed. This cannot be detected visually or reversed through refrigeration. Temperature-logging cold packs or data loggers are the only reliable verification that the peptide maintained required storage temperature throughout transit. Real Peptides includes temperature verification with every shipment specifically to eliminate this variable in research reproducibility.

Discard it immediately. Three hours at 20–25°C results in 1.5–2% potency loss through hydrolysis, but the larger issue is that you've now introduced an uncontrolled variable into your experimental protocol. You don't know the exact temperature it reached or how much degradation occurred. Using it compromises data reproducibility. Peptide costs less than the time and reagents you'll waste running experiments with compromised compounds.

Do not use the product for research. SS-LUP-332 requires continuous storage at −20°C from synthesis through delivery. Exposure to ambient temperatures (20–25°C) for more than 6 hours causes measurable degradation of the peptide structure. Even if the powder appears normal, temperature excursions compromise molecular stability in ways visual inspection can't detect. Document the shipping conditions with photos, contact the supplier for replacement with proper cold chain shipping, and if they refuse or claim ambient shipping is acceptable, source from a different supplier. This is a fundamental failure of peptide handling that indicates broader quality control problems.

Discard it. Follistatin-344 undergoes irreversible aggregation above 8°C. The peptide may still appear clear, but functional myostatin-binding capacity is compromised. There is no reliable way to test potency at home, and partial degradation means you're injecting an unknown dose. Temperature-compromised peptides are the single most common cause of 'non-responder' outcomes in strength protocols.

Reduce non-essential activity and maintain structured rest periods for 5–7 days while mitochondrial oxidative enzymes upregulate. The fatigue reflects temporary energy deficit as glycogen stores deplete faster than fat oxidation pathways mature. It's adaptive, not pathological. Subjects who maintain moderate activity (walking, light resistance training) rather than complete rest tend to resolve the transition faster because muscle contraction stimulates mitochondrial biogenesis.

Administer the dose again at the standard protocol level and measure markers at 6 hours instead of 2 hours. Initial transcriptional changes may not produce subjectively noticeable effects. Research relies on objective biomarkers like gene expression assays or metabolic chamber data, not perceived changes. If no measurable effect appears by 6 hours, verify reconstitution accuracy, storage temperature compliance, and compound source verification through third-party testing.

Stacking 5-Amino-1MQ with compounds like Tesofensine or CJC1295 Ipamorelin is common in research settings focused on metabolic optimisation. The mechanisms are complementary rather than redundant: 5-Amino-1MQ restores NAD+ availability for ATP synthesis, while growth hormone secretagogues like CJC1295/Ipamorelin increase lipolysis and lean mass accretion. Inject each peptide separately. Do not mix them in the same syringe. Administer 5-Amino-1MQ in the morning and GH secretagogues before bed to align with natural hormonal rhythms. Monitor fasting glucose closely if stacking with compounds that affect insulin sensitivity. NAD+ restoration can improve glucose uptake independently, and combining peptides may require dietary carbohydrate adjustments.

Use SLU-PP-332 at 1–5 µM in cell culture or 10–30 mg/kg/day in rodent models. The compound produces mitochondrial DNA replication and respiratory chain complex upregulation without activating AMPK or requiring PGC-1α, meaning you can study ERRα-driven transcription independently of energy stress pathways. Dose-response curves show linear increases in mitochondrial respiration from 0.5 µM to 10 µM with no plateau, allowing titration to match specific experimental endpoints.

Resume dosing at the next scheduled time without doubling the dose. SLU-PP-332's mitochondrial biogenesis effects are cumulative but not strictly linear. Missing one dose delays adaptation by 24–48 hours but does not reset progress. Continuous daily dosing over 7–14 days produces maximum adaptation; interruptions extend the timeline proportionally.

Time the dose 3–4 hours before activity to capture peak oxidative capacity during the session. SLU-PP-332 enhances fatty acid oxidation and lactate clearance, which benefits both endurance and high-intensity interval work. Though the compound's effects are more pronounced in sustained aerobic activity where mitochondrial density is the primary performance determinant. Short-duration explosive efforts (e.g., maximal lifts, sprints under 30 seconds) rely on phosphocreatine and glycolytic pathways less affected by mitochondrial function.

SLU-PP-332 serves as the positive control because it stabilizes ERRα in its active conformation independent of PGC-1α recruitment. Treat cells with SLU-PP-332 alongside PGC-1α overexpression. Additive effects confirm that ERRα and PGC-1α work through partially overlapping but non-redundant mechanisms. If PGC-1α knockdown abolishes the compound's effect, your endpoint depends on coactivator scaffolding, not direct receptor activation.

Monitor levels at day 7 and day 14. Transient elevations of 10–25 U/L above baseline are expected and resolve without intervention in >80% of cases. If AST/ALT exceed 80 U/L or remain elevated beyond 21 days, discontinue and assess for pre-existing hepatic stress. The elevation reflects increased free fatty acid processing, not liver damage, but persistent elevation suggests the liver isn't adapting as expected.

Mild redness or tenderness at the injection site is common during the first week and typically resolves as tissue adapts to subcutaneous peptide administration. Persistent swelling, heat, or spreading redness suggests either an allergic reaction to bacteriostatic water (rare but documented) or bacterial contamination introduced during reconstitution. Stop injections immediately and consult a healthcare provider. Switching to sterile water for injection (which requires refrigeration and daily reconstitution) eliminates benzyl alcohol exposure and resolves most sensitivity reactions. Rotate injection sites daily and ensure alcohol wipes dry completely before injecting. Wet alcohol increases irritation risk.

Split the daily dose into two smaller administrations separated by 8–12 hours to reduce peak plasma concentration impact on gut microbiome shifts. The GI response occurs because reduced glucose availability in the colon alters bacterial populations. Slower titration allows microbiome adaptation to occur gradually. Subjects using probiotics (Lactobacillus, Bifidobacterium strains) reported 40% lower GI symptom incidence in informal surveys.

SLU-PP-332 is the only ERR agonist that increases energy expenditure (via mitochondrial uncoupling in muscle) without cross-reacting with thyroid hormone receptors at therapeutic concentrations. Verify selectivity in your system using competitive binding assays or by co-treating with a TRβ antagonist. If metabolic effects persist, they're ERRα-mediated. This matters most in cardiac or hepatic models where thyroid activation confounds interpretation.

Check your injection technique and storage conditions first. If the peptide was stored above 8°C for more than 24 hours, it's likely denatured. Discard it and start with a fresh vial. NNMT inhibition is dose-dependent: 50mg may be subtherapeutic for individuals with chronically elevated NNMT expression (common in obesity and metabolic syndrome). Research protocols in these populations often titrate to 75mg daily. NAD+ restoration also requires adequate substrate availability. If dietary niacin intake is low or you're not supplementing NAD+ precursors, the peptide can only preserve what's already present, not create new NAD+ from nothing.

Discard the solution and reconstitute fresh peptide. SLU-PP-332 degrades rapidly above 8°C once in solution. 12 hours at room temperature reduces potency by approximately 10–15%, making dosing unpredictable. Lyophilised powder can tolerate brief temperature excursions (up to 25°C for 48 hours), but reconstituted solution cannot. Temperature control is non-negotiable for reliable onset times.

Verify dosing accuracy and storage conditions. SS-LUP-332 degrades rapidly at temperatures above 25°C and loses potency if exposed to light or moisture. If the compound was stored correctly and dosed appropriately (typical research range: 10–30 mg/kg in rodent models), lack of response may indicate individual variation in ERR receptor density or pre-existing mitochondrial adaptations from ketogenic dieting or endurance training that blunt the substrate-switching effect.

No. Use a selective SSRI like fluoxetine or citalopram instead. Tesofensine's value is its triple-reuptake profile. If your experimental design requires serotonin elevation without dopamine or norepinephrine interference, adding those variables confounds your results. Tesofensine is the right tool when you need to study serotonin in a physiologically realistic multimodal state, not when you need pharmacological isolation.